High-Efficiency Transduction and Long-Term Gene Expression with a Murine Stem Cell Retroviral Vector Encoding the Green Fluorescent Protein in Human Marrow Stromal Cells
Authors:
- James A. AllayJAJames A. Allay
- Derek A. PersonsDPDerek A. Persons
- Sharon A. NoonerSNSharon A. Nooner
- Phillip W. HargrovePHPhillip W. Hargrove
- Patrick F. KellyPKPatrick F. Kelly
- Elio F. VaninEVElio F. Vanin
- Edwin M. HorwitzEHEdwin M. Horwitz
- 1 May 1999
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 10 (7) , 1163-1173
Abstract
Bone marrow stromal cells (MSCs) are unique mesenchymal cells that have been utilized as vehicles for the delivery of therapeutic proteins in gene therapy protocols. However, there are several unresolved issues regarding their potential therapeutic applications. These include low transduction efficiency, attenuation of transgene expression, and the technical problems associated with drug-based selection markers. To address these issues, we have developed a transduction protocol that yields high-level gene transfer into human MSCs, employing a murine stem cell virus-based bicistronic vector containing the green fluorescent protein (GFP) gene as a selectable marker. Transduction of MSCs plated at low density for 6 hr per day for 3 days with high-titer viral supernatant resulted in a gene transfer efficiency of 80 +/- 6% (n = 10) as measured by GFP fluorescence. Neither centrifugation nor phosphate depletion increased transduction efficiency. Assessment of amphotropic receptor (Pit-2) expression by RT-PCR demonstrated that all MSCs expressing the receptor were successfully transduced. Cell cycle distribution profiles measured by propidium iodide staining showed no correlation with the susceptibility of MSCs to transduction by the retroviral vector. Human MSCs sequentially transduced with an adenoviral vector encoding the ecotropic receptor and ecotropic retroviral vector encoding GFP demonstrated that all MSCs are susceptible to retroviral transduction. We further showed that both genes of bicistronic vector are expressed for at least 6 months in vitro and that transgene expression did not affect the growth or osteogenic differentiation potential of MSCs. Future studies will be directed toward the development of gene therapy protocols employing this strategy.Keywords
This publication has 40 references indexed in Scilit:
- Retroviral Vector-Modified Bone Marrow Stromal Cells Secrete Biologically Active Factor IX In Vitro and Transiently Deliver Therapeutic Levels of Human Factor IX to the Plasma of Dogs after ReinfusionHuman Gene Therapy, 1998
- An Improved Method for Generating Retroviral Producer Clones for Vectors Lacking a Selectable Marker GeneBlood Cells, Molecules, and Diseases, 1998
- Bone Marrow Stromal Cells as Targets for Gene Therapy of Hemophilia AHuman Gene Therapy, 1998
- LacZ and Interleukin-3 Expression In Vivo after Retroviral Transduction of Marrow-Derived Human Osteogenic Mesenchymal ProgenitorsHuman Gene Therapy, 1997
- Green Fluorescent Protein Retroviral Vectors: Low Titer and High Recombination Frequency Suggest a Selective DisadvantageHuman Gene Therapy, 1997
- Systemic Delivery of Human Growth Hormone or Human Factor IX in Dogs by Reintroduced Genetically Modified Autologous Bone Marrow Stromal CellsHuman Gene Therapy, 1997
- Improved Gene Transfer into Human Lymphocytes Using Retroviruses with the Gibbon Ape Leukemia Virus EnvelopeHuman Gene Therapy, 1996
- Development and characterization of a conditionally transformed adult human osteoblastic cell lineJournal of Bone and Mineral Research, 1996
- Toward Gene Therapy for Hemophilia A: Long-Term Persistence of Factor VIII-Secreting Fibroblasts after Transplantation into Immunodeficient MiceHuman Gene Therapy, 1993
- Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.Journal of Cell Biology, 1975